NCT04327869

Brief Summary

The investigators aim to explore the feasibility of MCE in direct, real-time visualization of drug behavior in upper-gastrointestinal tract, which presented by the adhesion, distribution, and dissipation characteristics of dyed sucralfate gel.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 3, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 22, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 14, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 27, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 31, 2020

Completed
Last Updated

April 28, 2020

Status Verified

April 1, 2020

Enrollment Period

12 months

First QC Date

March 27, 2020

Last Update Submit

April 26, 2020

Conditions

Keywords

Magnetically controlled capsule endoscopysucralfate geldrug behaviorupper-gastrointestinal tract

Outcome Measures

Primary Outcomes (3)

  • Sucralfate gel adhesion behavior in the fasted gastric cavity

    The adhesion time was recorded from the sucralfate gel entered the stomach to all sucralfate adhered to the gastric wall.

    180 minutes

  • Sucralfate gel distribution behavior in the fasted gastric cavity

    The distribution area of sucralfate gel was measured by selecting images of six primary anatomic landmarks (cardia, fundus, body, angulus, antrum, and pylorus) at different times, the images were imported into MATLAB software to calculate the area of sucrafate gel. The dynamic changes of distribution area of sucralfate gel over the time were analyzed and performed with GraphPad Prism.

    0, 30, 60, 90, 150, 180 min after dyed sucralfate gel enter the stomach

  • Sucralfate gel dissipation behavior in the fasted gastric cavity

    The dissipation time was evaluated by calculating the times between sucralfate gel entered the stomach and adhered sucralfate disappeared completely.

    180 minutes

Secondary Outcomes (2)

  • Number of Participants with complications of MCE

    2 weeks

  • Discomfort scores of participants during the procedure

    during the procedure

Study Arms (2)

Abdominal symptoms group

The investigators selected 10 subjects (male: female = 1: 1) from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel

Device: Magnetically controlled capsule endoscopy

Healthy control group

The investigators selected another 10 subjects (male: female = 1: 1) from healthy volunteers.

Device: Magnetically controlled capsule endoscopy

Interventions

The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.

Abdominal symptoms groupHealthy control group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Volunteers who agreed to participate in the feasibility examination of MCE direct visualization of sucralfate gel behavior in fasted stomach.

You may qualify if:

  • With or without gastrointestinal complaints
  • Scheduled to undergo a capsule endoscopy for both stomach and small bowel
  • Signed the informed consents before joining this study

You may not qualify if:

  • Suspected or known gastrointestinal stenosis
  • Obstruction or other known risk factors for capsule retention
  • Pregnancy or suspected pregnancy
  • Pacemakers or electromedical devices implanted
  • Any other contraindications determined by endoscopists

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Changhai Hospital

Shanghai, 200433, China

Location

Related Publications (1)

  • Wang YC, Pan J, Jiang B, Qian YY, Qiu XO, Yuan YZ, Li ZS, Liao Z. Direct visualization of drug behaviors in the upper GI tract via magnetically controlled capsule endoscopy. VideoGIE. 2021 May 28;6(7):333-338. doi: 10.1016/j.vgie.2021.04.004. eCollection 2021 Jul.

MeSH Terms

Interventions

Endoscopy

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, SurgicalDiagnostic Techniques and ProceduresDiagnosisMinimally Invasive Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Zhuan Liao

    Changhai Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D., Associate Professor, Associate Chief Physician

Study Record Dates

First Submitted

March 27, 2020

First Posted

March 31, 2020

Study Start

November 3, 2018

Primary Completion

October 22, 2019

Study Completion

February 14, 2020

Last Updated

April 28, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

Locations